Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03020030 · ClinicalTrials.gov registry record · Phase 3
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
A Phase 3 study of Acute Lymphoblastic Leukemia, Pediatric, sponsored by Dana-Farber Cancer Institute.
- Active
- Registry status
- Phase 3
- Development phase
- 560
- Enrollment target
- 9
- Study locations
NCT03020030: Active Phase 3 study of Acute Lymphoblastic Leukemia, Pediatric, sponsored by Dana-Farber Cancer Institute.
NCT03020030 is a Phase 3 study of Acute Lymphoblastic Leukemia, Pediatric that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 560 participants, above the 54-participant average among 8 other Acute Lymphoblastic Leukemia, Pediatric trials with a reported enrollment target (937% higher). The trial reports 9 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03020030, a Phase 3 study of Acute Lymphoblastic Leukemia, Pediatric, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 560 participants
- Enrollment target
- 9
- Study locations
Study Summary
Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called lymphoblasts. They do not help fight infection and crowd out the normal blood cells in the bone marrow so that the body cannot make enough normal blood cells. ALL is always fatal if it is not treated. With current treatments, most children and adolescents with this disease will be cured. The standard treatment for ALL involves about 2 years of chemotherapy. The drugs that are used, and the doses of the drugs, are similar but not identical for all children and adolescents with ALL. Some children and adolescents receive stronger treatment, especially during the first several months. A number of factors are used to decide how strong the treatment should be to give the best chance for cure. These factors are called "risk factors". This trial is studying the use of a new, updated set of risk factors to decide how strong the treatment will be. The study also will test a new way of dosing a chemotherapy drug called pegaspargase (which is part of the standard treatment for ALL) based on checking levels of the drug in the blood and adjusting the dose based on the levels.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Pegaspargase
- DRUG Erwinia asparaginase
- DRUG CYTARABINE
- DRUG DASATINIB
Study Locations (9)
New York
- Roswell Park Cancer Institute - Buffalo
- Columbia University Medical Center, Morgan Stanley Children's Hospital of New York-Presbyterian - New York
- Montefiore Medical Center - The Bronx
Massachusetts
- Boston Children's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Quebec
- Hospital Sainte Justine, University of Montreal - Montreal
- Centre Hospitalier U. de Quebec - Québec
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
Rhode Island
- Hasbro Children's Hospital / Rhode Island Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 560 participants |
| Start Date | 2017-03-03 |
| Est. Completion | 2034-11 |
| Phase | Phase 3 |
What the registry record for NCT03020030 still lists
NCT03020030 is an interventional study that assigns participants to a tested intervention. The registered 560 participants enrollment target is mid-sized for trials with a published cap, above the 54-participant average among 8 other Acute Lymphoblastic Leukemia, Pediatric trials with a reported enrollment target (937% higher).
The record links to 1 condition, with Acute Lymphoblastic Leukemia, Pediatric appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03020030 lists 9 locations in 5 states (New York, Massachusetts, Quebec).
Frequently Asked Questions
What is clinical trial NCT03020030 about?
NCT03020030 is a clinical study titled "Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents". Acute lymphoblastic leukemia (ALL) is the most common cancer diagnosed in children. The cancer comes from a cell in the blood called a lymphocyte. Normal lymphocytes are produced in the bone marrow (along with other blood cells) and help fight infections. In ALL, the cancerous lymphocytes are called...
What is the current status of trial NCT03020030?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 560 participants. The study started on 2017-03-03. Estimated completion is 2034-11.
What conditions does trial NCT03020030 study?
This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia, Pediatric.
What interventions are being tested in trial NCT03020030?
The interventions under investigation include: Cyclophosphamide (DRUG), Pegaspargase (DRUG), Erwinia asparaginase (DRUG), CYTARABINE (DRUG), DASATINIB (DRUG).
Who is sponsoring clinical trial NCT03020030?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03020030 being conducted?
This trial has 9 study locations across Massachusetts, New Jersey, New York, Rhode Island, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Lymphoblastic Leukemia, Pediatric
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03020030's enrollment target sits among peer trials
560 1st of 8 higher than 8 of 8 other Acute Lymphoblastic Leukemia, Pediatric trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Lymphoblastic Leukemia, Pediatric trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain MRF in Children, Adolescents and Young Adults With Acute Leukemia
RECRUITING · NA
-
Behavioral Parenting Skills as a Novel Target for Improving Pediatric Medication Adherence: Study 3
RECRUITING · NA
-
Palbociclib in Combination With Chemotherapy in Pediatric Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (RELPALL2)
RECRUITING · Phase 1
-
Massage Impact on Sleep in Pediatric Oncology
RECRUITING · NA
-
Virtual Reality During Lumbar Punctures in Acute Lymphoblastic Leukemia
RECRUITING · NA
-
CD22-CAR T Cells in Children and Young Adults With B Cell Malignancies
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04661358 · 560 participants · Phase 3
Fenofibrate for Prevention of DR Worsening
- NCT05473871 · 560 participants · NA
Enhancing Capacity in Churches to Implement PA Programs
- NCT06001541 · 560 participants · NA
Web-based Program to Improve Self-management Among Veterans-caregiver Dyads
- NCT06246916 · 560 participants · Phase 3
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI